Suppr超能文献

[口服依托泊苷成功用于成人T细胞白血病病例的长期每日给药]

[Successful chronic daily administration of oral etoposide for a case of adult T cell leukemia].

作者信息

Matsuoka H, Toyama T, Horinouchi M, Maeda K, Suzuki M, Kubuki Y, Komura K, Ishikawa T, Uno H, Tsubouchi H

机构信息

Second Dept. of Internal Medicine, Miyazaki Medical School.

出版信息

Gan To Kagaku Ryoho. 1993 Aug;20(10):1387-90.

PMID:8346938
Abstract

A 54-year-old woman with leucocytosis and skin lesion was hospitalized and diagnosed as chronic type adult T cell leukemia (ATL) in August 1989. Since her ATL cell count and LDH level increased after hospitalization, oral administration of etoposide was started at a dose of 100 mg/day for seven days. The oral administration of etoposide induced another chronic state of ATL. After 10 months without medication, she was readmitted because of an acute ATL crisis. After daily administration of etoposide at a dose of 50 mg/day, the white blood cell count and serum LDH level decreased to the normal range, and abnormal lymphocytes of peripheral blood disappeared. The low-dose daily administration of etoposide at a dose of 25 approximately 50 mg/day could be maintained over six months. No severe side effects except for alopecia and mild myelosuppression were noted during the treatment. Chronic daily administration of oral etoposide is one candidate for the treatment of ATL in an outpatient clinic.

摘要

一名54岁白细胞增多且有皮肤损害的女性于1989年8月住院,被诊断为慢性型成人T细胞白血病(ATL)。住院后其ATL细胞计数和乳酸脱氢酶(LDH)水平升高,遂开始口服依托泊苷,剂量为100毫克/天,共7天。口服依托泊苷诱发了ATL的另一种慢性状态。在停药10个月后,她因急性ATL危象再次入院。每日给予50毫克/天的依托泊苷后,白细胞计数和血清LDH水平降至正常范围,外周血异常淋巴细胞消失。低剂量每日给予约25至50毫克/天的依托泊苷可维持6个月以上。治疗期间除脱发和轻度骨髓抑制外未观察到严重副作用。门诊慢性每日口服依托泊苷是治疗ATL的一种选择。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验